Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells $411,624.42 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,218 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $33.69, for a total transaction of $411,624.42. Following the sale, the chief operating officer directly owned 85,033 shares in the company, valued at approximately $2,864,761.77. The trade was a 12.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Stock Performance

Shares of CSTL opened at $33.50 on Friday. The business has a fifty day moving average of $27.24 and a 200 day moving average of $25.47. The firm has a market capitalization of $1.02 billion, a P/E ratio of -50.76 and a beta of 0.98. Castle Biosciences, Inc. has a one year low of $17.72 and a one year high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. As a group, sell-side analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Institutional Investors Weigh In On Castle Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC purchased a new position in shares of Castle Biosciences in the 2nd quarter valued at approximately $26,000. Federated Hermes Inc. acquired a new position in Castle Biosciences during the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the fourth quarter worth about $35,000. Jones Financial Companies Lllp boosted its position in Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after buying an additional 297 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CSTL has been the subject of a number of analyst reports. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. BTIG Research increased their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Finally, Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.